Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Journal of Visualized Experiments · 2025
DOI: 10.3791/68933 ↗Kurz gefasst
Video/Audio in der Zeitschrift Journal of Visualized Experiments, 2025. Verfasst von L J Córdova-Bahena und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Universidad Nacional Autónoma de México (UNAM); Investigadores por México, Secretaría de Ciencia, Humanidades, Tecnología e Innov…. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus 3C Proteases, COVID-19 Drug Treatment, Small Molecule Libraries. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Universidad Nacional Autónoma de México (UNAM); Investigadores por México, Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI).
- Research and Development in Biotherapeutics Unit (UDIBI), National School of Biological Sciences, National Polytechnic Institute; National Laboratory for Specialized Services of Investigation, Development and Innovation…
- School of Medicine, Universidad Nacional Autónoma de México (UNAM); marcovelasco@unam.mx.
Zitieren
APA
Córdova-Bahena, L. J., Pérez-Tapia, S. M., & Velasco-Velázquez, M. A. (2025). Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro. Journal of Visualized Experiments. https://doi.org/10.3791/68933
Vancouver
Córdova-Bahena LJ, Pérez-Tapia SM, Velasco-Velázquez MA. Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro. Journal of Visualized Experiments. 2025. doi:10.3791/68933
BibTeX
@article{CrdovaBahena2025,
author = {Córdova-Bahena, L J and Pérez-Tapia, S M and Velasco-Velázquez, Marco A},
title = {Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro},
journal = {Journal of Visualized Experiments},
year = {2025},
doi = {10.3791/68933}
}
EUVIMED